Emergent BioDefense Gains FDA Approval Letter Update for BioThrax Post-Exposure Prophylaxis Labeling

A November 5, 2025 approval letter from FDA updates the labeling record for BioThrax, Emergent BioDefense Operations Lansing LLC's Anthrax Vaccine Adsorbed, with direct implications for biologics manufacturers tracking post-exposure prophylaxis (PEP) labeling standards and compliance posture under 21 CFR Part 600.

BioThrax (STN: BL 103821) carries two approved indications: pre-exposure prophylaxis for persons at high risk of Bacillus anthracis exposure, and post-exposure prophylaxis following suspected or confirmed anthrax exposure, the latter contingent on concurrent administration of recommended antibacterial drugs. The approved population is adults aged 18 through 65. The PEP indication's conditional language, requiring co-administration of antibacterials, is a labeling precision point that QA and regulatory affairs teams at other biologics facilities should note when benchmarking their own combination-use labeling against current FDA expectations.

For plant heads and QA directors at biologics manufacturing sites, the updated approval letter signals that FDA continues to maintain an active labeling review cycle for this product under its biologics license. Emergent BioDefense Operations Lansing LLC, as the named manufacturer, carries the corresponding obligation to ensure distributed product labeling aligns with the approved text, a requirement that sits squarely within ICH Q10 pharmaceutical quality system expectations for change management and document control. Any divergence between distributed labeling and the approved package insert would constitute a significant GMP deviation under biologics regulations.

Supporting documentation older than three years has been archived separately in FDA's records, a routine administrative action that nonetheless affects how regulatory affairs leads should structure their labeling history files when preparing for BLA supplements or responding to agency information requests. The FDA Online Label Repository carries a standing caveat that repository content may not reflect currently distributed labeling, reinforcing the need to verify against the approval letter directly.

The November 2025 approval letter now stands as the controlling labeling reference for BioThrax, and biologics manufacturers with comparable PEP-indicated products should cross-reference their own labeling against this update ahead of their next scheduled label review cycle.

Source: FDA Vaccines, Blood and Biologics / What's New RSS Feed, August 13, 2026.